This week, we will discuss the MENTOR trial, which pitted rituximab versus cyclosporine for membranous nephropathy
This week, we will discuss an RCT, a pediatric RCT, and a pediatric RCT in childhood nephrotic syndrome! A trial that asks a question of burning importance to the management of childhood nephrotic syndrome. Join us as we tackle PREDNOS.
Atrosentan makes a return visit to NephJC, but now it goes beyond changes in proteinuria and shows improved kidney outcomes. Is it enough to overcome the fluid complications?
This week, we will discuss a risk score which helps to prognosticate the most common glomerular disease. Not only is IgA most common - it is quite heterogeneous, which makes the problem of who should get treated quite difficult.
Great to have First Author, Jessica Tangren join us!
Anna Burgner made her debut hosting the American Chat, and Ben did a great job as always with the EU version
New rule for visual abstract. We need to stop adding the logo of the publishing journal. Replace the logo with the authors name. So here is the latest visual abstract in the new style.
